Heart Failure: Evolving Treatment Choices and New Guidance

Heart Failure: Evolving Treatment Choices and New Guidance is organized by Rockpointe Corporation.,Release Date: Oct 24, 2022,Expiration Date: Oct 24, 2023,Description:,The number of Americans with HF is increasing. Despite the many agents approved to manage HF, the prognosis has only improved somewhat, with a 5-year mortality rate after initial hospitalization of 42.3%. Guidelines are frequently updated, with the most recent ACC consensus on optimizing treatment published in 2022. Some agents to treat HFrEF are relatively new and several agents are in late-stage development. For patients with HFpEF, there are currently no approved therapies although there are agents in phase 3 clinical trials.,Heart Failure: Evolving Treatment Choices and New Guidance will address the rapidly shifting HF management paradigm, providing information about the most recent evidence-based recommendations for managing HFrEF, newer approved agents, and those agents for which approval is anticipated soon, as well as agents in the late-stage investigation for the management of HFpEF.,Educational Objectives:,At the conclusion of this education, participants should be able to:,• Evaluate the evidence showing the efficacy and safety of newer agents approved for the management of HFrEF,• Describe the mechanism of action of and efficacy and safety data for agents in late-stage development for the management of heart failure,• Develop individualized evidence-based management plans for patients with heart failure that are based on recommendations from the 2021 update to the ACC heart failure decision pathway